GOVX Quote, Financials, Valuation and Earnings

Chimerix has a net margin of -208.48% compared to Geovax Labs's net margin of -87996.15%. Geovax Labs's return on equity of -575.49% beat Chimerix's return on equity of -48.22%.

Geovax Labs has a consensus price target of $14.60, signalling upside risk potential of 546.02%. On the other hand Chimerix has an analysts' consensus of -- which suggests that it could grow by 151.5%. Given that Geovax Labs has higher upside potential than Chimerix, analysts believe Geovax Labs is more attractive than Chimerix.

Geovax Labs has a beta of 3.242, which suggesting that the stock is 224.241% more volatile than S&P 500. In comparison Chimerix has a beta of 1.018, suggesting its more volatile than the S&P 500 by 1.827%.

Geovax Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Chimerix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geovax Labs pays -- of its earnings as a dividend. Chimerix pays out -- of its earnings as a dividend.

Geovax Labs quarterly revenues are $2.8M, which are larger than Chimerix quarterly revenues of $26K. Geovax Labs's net income of -$5.8M is higher than Chimerix's net income of -$22.9M. Notably, Geovax Labs's price-to-earnings ratio is -- while Chimerix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geovax Labs is -- versus -- for Chimerix. Usually stocks with elevated PS ratios are considered overvalued.

Emergent BioSolutions has a net margin of -208.48% compared to Geovax Labs's net margin of 40.45%. Geovax Labs's return on equity of -575.49% beat Emergent BioSolutions's return on equity of -35.94%.

Geovax Labs has a consensus price target of $14.60, signalling upside risk potential of 546.02%. On the other hand Emergent BioSolutions has an analysts' consensus of $12.00 which suggests that it could grow by 44.58%. Given that Geovax Labs has higher upside potential than Emergent BioSolutions, analysts believe Geovax Labs is more attractive than Emergent BioSolutions.

Geovax Labs has a beta of 3.242, which suggesting that the stock is 224.241% more volatile than S&P 500. In comparison Emergent BioSolutions has a beta of 1.594, suggesting its more volatile than the S&P 500 by 59.352%.

Geovax Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Emergent BioSolutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geovax Labs pays -- of its earnings as a dividend. Emergent BioSolutions pays out -- of its earnings as a dividend.

Geovax Labs quarterly revenues are $2.8M, which are smaller than Emergent BioSolutions quarterly revenues of $283.8M. Geovax Labs's net income of -$5.8M is lower than Emergent BioSolutions's net income of $114.8M. Notably, Geovax Labs's price-to-earnings ratio is -- while Emergent BioSolutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geovax Labs is -- versus 0.40x for Emergent BioSolutions. Usually stocks with elevated PS ratios are considered overvalued.

SIGA Technologies has a net margin of -208.48% compared to Geovax Labs's net margin of 13.43%. Geovax Labs's return on equity of -575.49% beat SIGA Technologies's return on equity of 52.07%.

Geovax Labs has a consensus price target of $14.60, signalling upside risk potential of 546.02%. On the other hand SIGA Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Geovax Labs has higher upside potential than SIGA Technologies, analysts believe Geovax Labs is more attractive than SIGA Technologies.

Geovax Labs has a beta of 3.242, which suggesting that the stock is 224.241% more volatile than S&P 500. In comparison SIGA Technologies has a beta of 0.891, suggesting its less volatile than the S&P 500 by 10.87%.

Geovax Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SIGA Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.60 per share. Geovax Labs pays -- of its earnings as a dividend. SIGA Technologies pays out 47.21% of its earnings as a dividend. SIGA Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Geovax Labs quarterly revenues are $2.8M, which are smaller than SIGA Technologies quarterly revenues of $10M. Geovax Labs's net income of -$5.8M is lower than SIGA Technologies's net income of $1.3M. Notably, Geovax Labs's price-to-earnings ratio is -- while SIGA Technologies's PE ratio is 5.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geovax Labs is -- versus 2.48x for SIGA Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Tonix Pharmaceuticals Holding has a net margin of -208.48% compared to Geovax Labs's net margin of -503.65%. Geovax Labs's return on equity of -575.49% beat Tonix Pharmaceuticals Holding's return on equity of -150.01%.

Geovax Labs has a consensus price target of $14.60, signalling upside risk potential of 546.02%. On the other hand Tonix Pharmaceuticals Holding has an analysts' consensus of $5.83 which suggests that it could grow by 1413.97%. Given that Tonix Pharmaceuticals Holding has higher upside potential than Geovax Labs, analysts believe Tonix Pharmaceuticals Holding is more attractive than Geovax Labs.

Geovax Labs has a beta of 3.242, which suggesting that the stock is 224.241% more volatile than S&P 500. In comparison Tonix Pharmaceuticals Holding has a beta of 2.232, suggesting its more volatile than the S&P 500 by 123.214%.

Geovax Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tonix Pharmaceuticals Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geovax Labs pays -- of its earnings as a dividend. Tonix Pharmaceuticals Holding pays out -- of its earnings as a dividend.

Geovax Labs quarterly revenues are $2.8M, which are smaller than Tonix Pharmaceuticals Holding quarterly revenues of $2.8M. Geovax Labs's net income of -$5.8M is higher than Tonix Pharmaceuticals Holding's net income of -$14.2M. Notably, Geovax Labs's price-to-earnings ratio is -- while Tonix Pharmaceuticals Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geovax Labs is -- versus 0.60x for Tonix Pharmaceuticals Holding. Usually stocks with elevated PS ratios are considered overvalued.